Table 1 Updated DLT probabilities of the five tested dose levels, computed after each newly included cohort of three patients per dose level through the use of Bayes theorem

From: A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia

   

HHT-loading dose (mg m−2 day−1)

   

Initial guesses of toxicity probability

   

0.5

1

3

5

6

   

Updated estimated probability of DLT

Cohort

Administrated dose (mg m−2 day−1)

Clinical response

0.5

0.1

0.15

0.33

0.50

1

0.5

NT NT NT

0.001

0.003

0.006

0.035

0.11

2

3

NT NT T

0.07

0.14

0.19

0.39

0.55

3

5

NT NT T

0.07

0.13

0.19

0.38

0.54

4

5

NT NT NT

0.03

0.07

0.11

0.27

0.45

5

5

NT T NT

0.04

0.08

0.12

0.29

0.46

6

5

T NT T

0.06

0.12

0.17

0.36

0.53

  1. DLT=dose-limiting toxicity; HHT=homoharringtonine; NT=no toxicity; T=DLT.
  2. In bold: the dose level closest to the toxicity target (33%).